AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03967314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TLIP block group (group T)
Description: In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
Study NCT03967314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration group (group W)
Description: In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
Study NCT02537860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo at T11 and L3
Description: Two injections that contain saline are performed
Study NCT02537860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block injections between T11 and L3
Description: Five anesthetic injections are done
Study NCT02537860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniorrhaphy
Description: Unilateral inguinal hernia repair
Study NCT02537860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) fentanyl
Description: Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
Study NCT02537860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Each patient will receive 75 mg bupivacaine during PVB
Study NCT02484261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
Study NCT02484261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages >14 years
Study NCT03666767 — intervention group
Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.
Study NCT02273973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
Study NCT02273973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
Study NCT02273973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
Study NCT02273973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
Study NCT01676116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
Study NCT01676116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Study NCT01676116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Study NCT01064089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP990
Study NCT02207387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect
Description: Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
Study NCT02207387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
Study NCT00428298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take two 500 mg capsules twice daily for 16 weeks.
Study NCT01901263 — intervention group
Intervention type: BEHAVIORAL
Intervention: patients with alzheimer's disease
Description: the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
Study NCT02261389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm B, tumor markers assessment
Description: Tumor markers assessment every three months through the study or until disease recurrence
Study NCT01836380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Study NCT04188080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg Cheese
Description: Oral daily intake of Jarlsberg cheese
Study NCT02207387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Study NCT03887910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
Study NCT03887910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
Study NCT03144050 — intervention group
Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device
Study NCT03347487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimuation system implantation
Description: All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
Study NCT02543489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Flex IM rod
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metacavir Enteric-coated Capsules 80mg
Description: Metacavir Enteric-coated Capsules 80mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules 160mg
Description: Metacavir Enteric-coated Capsules 160mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules 320mg
Description: Metacavir Enteric-coated Capsules 320mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metacavir Enteric-coated Capsules Placebo 240mg
Description: Metacavir Enteric-coated Capsules Placebo 240mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 160mg
Description: Metacavir Enteric-coated Capsules Placebo 160mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 320mg
Description: Metacavir Enteric-coated Capsules Placebo 320mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 320mg
Description: Metacavir Enteric-coated Capsules Placebo 320mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule10mg
Description: Adefovir Dipivoxil Capsule10mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg
Study NCT02965859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg
Study NCT05167474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breast milk smell
Description: yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
Study NCT04653363 — intervention group
Intervention type: OTHER
Intervention: assessments
Description: All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
Study NCT01964053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATCH intervention
Description: The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
Study NCT01964053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
Study NCT03264339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Step Program
Description: The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
Study NCT04521426 — intervention group
Intervention type: OTHER
Intervention: No other than standard care
Description: No other than standard care.
Study NCT02652819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Study NCT02652819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00833209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (withdrawal)
Description: 3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
Study NCT00833209 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: 2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
Study NCT00833209 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: 1 MRI ; Iowa Gambling Task test and questionnaires.
Study NCT03575650 — intervention group
Intervention type: OTHER
Intervention: Cardiac imaging modalities
Description: Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
Study NCT03364192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Health Coaching
Description: Veterans Health Administration variation of integrative health coaching.
Study NCT04545307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
Description: The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
Study NCT03906695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 5mg + cedazuridine
Study NCT03906695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 10mg + cedazuridine
Study NCT03906695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 20mg + cedazuridine
Study NCT01887210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Gaming Adherence Intervention
Description: Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
Study NCT01887210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Smart pill bottle cap and mobile phone but no game
Study NCT01998646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4058
Description: Oral tablet
Study NCT01998646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT02900677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and nutrition program
Description: 6 education programs with physical enhancement and nutrition related information for 12 weeks
Study NCT00680732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplements (MMS)
Description: Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
Study NCT00680732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: Iron 60 mg and folic acid 400 mcg
Study NCT00680732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Description: Tablets 100 mg of chloroquine base
Study NCT00680732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxyne-pyrimethamine (SP)
Description: Tablets
Study NCT00687050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: peroral high-caloric supplemental nutrition
Description: HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
Study NCT00687050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: peroral supplemental nutrition
Description: Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
Study NCT01388400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy
Description: upper limb exercises
Study NCT01388400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video capture virtual reality
Description: virtual reality delivered uppe limb exercises
Study NCT02551172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1105
Description: Rosuvastatin + Omega-3-acids ethyl esters
Study NCT02551172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HGP0816
Description: Rosuvastatin
Study NCT02551172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Description: Rosuvastatin
Study NCT02551172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HCP1105
Description: Soybean Oil
Study NCT02551172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of HGP0816
Description: Exclusion of Rosuvastatin in HGP0816
Study NCT04374864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Anti diabetic
Study NCT02557035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Study NCT02557035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Study NCT02557035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02557035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00835081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg Capsules
Description: 1 x 500 mg
Study NCT00835081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DURICEF® capsules 500 mg
Description: 1 x 500 mg
Study NCT00256230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF)
Description: DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
Study NCT02362997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study NCT02891863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEVER Acute Study System
Description: The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
Study NCT01299935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
Study NCT01299935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
Study NCT02765724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
Study NCT02183311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - single rising dose
Study NCT02183311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - multiple rising dose
Study NCT02183311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03036748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized sodium diet
Description: Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
Study NCT03036748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbl amiloride
Description: Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day